We Understand Chronic Conditions
and Related Therapy Challenges
Atrial fibrillation – We conducted an extensive study of the atrial fibrillation market landscape including patient flow and the use of oral factorXa inhibitors.
Chronic pain – We have studied chronic pain, its sources, medications and modes of administration including intrathecal drug delivery systems (IDDS).
Diabetes – We have studied diabetes directly and as a significant co-morbidity and potential contributor to several conditions, including dyslipidemia and hypertension, as well as diabetes’ potential role in increasing risk of certain cancers (e.g., liver, breast, bladder).
Hep C – We have experience in studying Hep C and have researched hepatitis for more than 15 years. Our research includes HCV, HAV, HBC, and EBV as well as numerous treatments and combinations of treatments for these conditions and their co-morbidities, including HIV.
HIV / AIDS – Our firm's scientists have done extensive research in the HIV / AIDS market for two decades, including several studies on AIDS-related infections.
Hypertension – We have studied major causal factors of heart disease, including hypertension and hyperlipidemia. Much of our cardio research has focused on hypertensive heart disease.
Multiple sclerosis – Our experience in MS and RRMS extends back to the clinical internship in a Virginia state hospital of Clarity’s founder, Dr. Jack Gallagher, during which he worked with more than 100 MS patients and adults. Clarity since has studied MS issues such as spasticity and exacerbations, as well as various treatments, including biologics, steroids, and interferons, and modes of administration including intrathecal drug delivery systems (IDDS).
Psoriasis – We have conducted multiple studieson forms of psoriasis and related treatments, including vitamin therapy, corticosteroids, biologics such as those also used for rheumatoid arthritis, photo/light therapy, methotrexate, and the immunosuppressant cyclosporine.
Rheumatoid arthritis – Our studies have focused on important subpopulations of the disorder, e.g., RA patients with chronic kidney disease or with anemia.